Psoriasis, Aifa green light to reimbursement of deucravacitinib for moderate and severe forms

People with moderate to severe psoriasis now have a new treatment option. It is deucravacitinib, the first-in-class tyrosine kinase inhibitor drug that has been approved for reimbursement by the Italian Medicines Agency (AIFA). The green light from AIFA was the focus of the press conference organized by Bristol Myers Squibb in Rome.